

Elevate the standard of cervical cancer screening

HPV extended genotyping is an innovative screening tool to enhance clinical management.

Individual identification of high-risk genotypes is essential to reveal the true risk of CIN3+ disease^{*,1}

Partial genotyping:

Only 2 high-risk HPV types individually identified



16

18

high risk
other

Extended genotyping with BD Onclarity™ HPV Assay:

6 high-risk HPV types individually identified



16

18

45

31

52

51

35
39 68

33
58

56
59 66




Individual results



Pooled results

BD Onclarity™ HPV Assay has officially been added to the ASCCP guidelines

The American Society for Colposcopy and Cervical Pathology (ASCCP) has separated the BD Onclarity™ HPV Assay channels into three different risk-based tiers, which inform new clinical recommendations.²



It's time to redefine screening and make powerful progress towards **eliminating cervical cancer**

Learn more about BD Onclarity™ HPV Assay

*CIN, cervical intraepithelial neoplasia.

*Note: Dual Stain is not FDA approved for use as a triage with BD Onclarity™ HPV Assay

References:

1. Bonde JH et al. *J Low Genit Tract Dis.* 2020;24(1):1–13.
2. ASCCP. Management Guidelines and the Enduring Guidelines Process. Accessed February 2025.

bd.com

BD, the BD logo, and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates.
All other trademarks are the property of their respective owners. ©2025 BD. All rights reserved. (BD-145682 3975-US-0325 March 2025)

